Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Elborn

Showing results (171-180 of 326) with videos related to

Pageof 33
Sort By:
BMC Pulmonary Medicine|October 31, 2020
New strategies of physical activity assessment in cystic fibrosis: a pilot studyDaniela Savi, Luigi Graziano, Barbara Giordani, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 17, 2014
Indicators of pulmonary exacerbation in cystic fibrosis: A Delphi survey of patients and health professionalsFiona McCourt, Brenda O'Neill, Ian Logan, et al.
Respiratory Medicine|August 6, 2016
Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasisRobert Wilson, Timothy Aksamit, Stefano Aliberti, et al.
Microbiology Resource Announcements|June 8, 2019
Draft Genome Sequence of Haemophilus haemolyticus Strain 16/010 O, Isolated from a Sputum Sample from a Cystic Fibrosis PatientAd C Fluit, Jumamurat R Bayjanov, Michael Tunney, et al.
The European Respiratory Journal|July 7, 2017
Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with <i>Pseudomonas aeruginosa</i>Sally H Pattison, David S Gibson, Elinor Johnston, et al.
The Lancet. Respiratory Medicine|June 15, 2016
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysisJ Stuart Elborn, Bonnie W Ramsey, Michael P Boyle, et al.
Photodiagnosis and Photodynamic Therapy|February 22, 2011
Drug and light delivery strategies for photodynamic antimicrobial chemotherapy (PACT) of pulmonary pathogens: a pilot studyCorona M Cassidy, Michael M Tunney, Nicholas D Magee, et al.
Pediatric Pulmonology|April 18, 2006
Association of improved pulmonary phenotype in Irish cystic fibrosis patients with a 3' enhancer polymorphism in alpha-1-antitrypsinJulia M Courtney, Barry J Plant, Kevin Morgan, et al.
Plos One|October 11, 2012
The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbationsAnthony A Fodor, Erich R Klem, Deirdre F Gilpin, et al.
The Lancet. Respiratory Medicine|June 14, 2015
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trialRichard B Moss, Patrick A Flume, J Stuart Elborn, et al.
Pageof 33

Showing results (171-180 of 326) with videos related to

Sort By:
Pageof 33
BMC Pulmonary Medicine|October 31, 2020
New strategies of physical activity assessment in cystic fibrosis: a pilot studyDaniela Savi, Luigi Graziano, Barbara Giordani, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 17, 2014
Indicators of pulmonary exacerbation in cystic fibrosis: A Delphi survey of patients and health professionalsFiona McCourt, Brenda O'Neill, Ian Logan, et al.
Respiratory Medicine|August 6, 2016
Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasisRobert Wilson, Timothy Aksamit, Stefano Aliberti, et al.
Microbiology Resource Announcements|June 8, 2019
Draft Genome Sequence of Haemophilus haemolyticus Strain 16/010 O, Isolated from a Sputum Sample from a Cystic Fibrosis PatientAd C Fluit, Jumamurat R Bayjanov, Michael Tunney, et al.
The European Respiratory Journal|July 7, 2017
Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with <i>Pseudomonas aeruginosa</i>Sally H Pattison, David S Gibson, Elinor Johnston, et al.
The Lancet. Respiratory Medicine|June 15, 2016
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysisJ Stuart Elborn, Bonnie W Ramsey, Michael P Boyle, et al.
Photodiagnosis and Photodynamic Therapy|February 22, 2011
Drug and light delivery strategies for photodynamic antimicrobial chemotherapy (PACT) of pulmonary pathogens: a pilot studyCorona M Cassidy, Michael M Tunney, Nicholas D Magee, et al.
Pediatric Pulmonology|April 18, 2006
Association of improved pulmonary phenotype in Irish cystic fibrosis patients with a 3' enhancer polymorphism in alpha-1-antitrypsinJulia M Courtney, Barry J Plant, Kevin Morgan, et al.
Plos One|October 11, 2012
The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbationsAnthony A Fodor, Erich R Klem, Deirdre F Gilpin, et al.
The Lancet. Respiratory Medicine|June 14, 2015
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trialRichard B Moss, Patrick A Flume, J Stuart Elborn, et al.
Pageof 33